Description
Key facts
Detection method:Colorimetric,
Sample types:Urine, Plasma, Cell culture supernatant, Serum,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 6 pg/mL,
Range:31.25 - 2000 pg/mL,
Assay time:1h 30m,
Assay Platform:Microplate
Product details:
Human Apolipoprotein A II ELISA kit (ab184859) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Apolipoprotein A II protein in human serum, plasma, urine, cell culture supernatant samples. It uses our proprietary SimpleStep ELISA® technology. Quantitate human Apolipoprotein A II with 6 pg/mL sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
-Single-wash protocol reduces assay time to 90 minutes or less
-High sensitivity, specificity and reproducibility from superior antibodies
-Fully validated in biological samples
-96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpeStep ELISA® kits.
Apolipoprotein AII may stabilize HDL (high density lipoprotein) structure by its association with lipids, and affect the HDL metabolism. ApoA2 forms a disulfide-linked homodimer. Apolipoprotein AII also forms a disulfide-linked heterodimer with APOD and interacts with HCV core protein, APOA1BP and NDRG1.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Apolipoprotein A-II (also known as ApoA-II or Apolipoprotein A2) is a pivotal protein component of high-density lipoproteins (HDL) in the plasma. It is encoded by the APOA2 gene in humans and displays a molecular mass of approximately 17.4 kDa. Apolipoprotein A-II is primarily expressed in the liver and secreted into the bloodstream where it plays a direct role in lipid metabolism. Its structural composition includes a highly amphipathic α-helical structure that facilitates interaction with lipids aiding in lipoprotein formation and stability.
Biological function summary
Apolipoprotein A-II serves as a significant regulator of HDL metabolism and lipid transport. It is an integral part of HDL particles contributing to their stability and function. Apolipoprotein A-II influences lecithin-cholesterol acyltransferase (LCAT) activity which affects cholesterol esterification. Although less studied than its counterpart Apolipoprotein A-I ApoA-II's interaction with lipids and proteins such as CETP (cholesteryl ester transfer protein) suggests its involvement in lipid exchange and reverse cholesterol transport processes.
Pathways
Apolipoprotein A-II impacts the reverse cholesterol transport pathway and lipid metabolic processes. ApoA-II works closely with its relative Apolipoprotein A-I both part of the same HDL complex. Together they play essential roles in maintaining cholesterol homeostasis and promoting cholesterol efflux from cells back to the liver. The mechanism by which it modulates the function of lipoprotein lipase and hepatic lipase further implicates its role in lipid metabolism and energy balance processes.
Dysfunction or abnormal levels of Apolipoprotein A-II have associations with cardiovascular diseases and metabolic syndromes. Altered ApoA-II levels correlate with an increased risk of atherosclerosis as its imbalance can drive perturbations in HDL composition and function. Moreover research links Apolipoprotein A-II with insulin resistance linking it with ApoA-I imbalanced lipid transport and metabolism in obesity and diabetes contexts. Understanding these connections may guide therapeutic strategies targeting ApoA-II to mitigate the risks and progression of these disorders.
